Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180032/S023

Cerene Cryotherapy Device

Channel Medsystems, Inc. · Decision date Jul 8, 2026

FDA DECISIONP180032/S023

What did the FDA approve?

FDA records P180032/S023 as a supplement to PMA P180032, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Jul 8, 2026.

FDA approval order statement

The recommended decision for this file is Approve PMA GMP without inspection. This recommendation is based on transferring a low-risk labeling activity to a manufacturing site (and sponsor) previously approved under the PMA.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Obstetrics/Gynecology
Decision date
Jul 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P180032/S023
Regulatory pathway
PMA supplement
Product code
MNB
Decision code
APPR
Decision date
Jul 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Device, thermal ablation, endometrial.

Product code
MNB
FDA device class
3

For the original device and its historical approval scope, see PMA P180032. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180032 · Original PMA

    Cerene Cryotherapy Device

  2. P180032/S022 · Related supplement

    Cerene Cryotherapy Device

  3. P180032/S023 received

    Application receipt date recorded by FDA.

  4. P180032/S023 · FDA decision

    Normal 180 Day Track

  5. P180032/S024 · Related supplement

    Cerene Cryotherapy Device

  6. P180032/S025 · Related supplement

    Cerene Cryotherapy Device (Model number FGS-7000); Exhaust Collection Bag (Model number FGS-8000); Exhaust Collection Ba

Timeline entries are records held by MedtechLedger for P180032. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180032

Product / regulatory recordCompanyPathwayDecision dateSource
Channel Medsystems, Inc.PMA approvalMar 28, 2019FDA
Channel Medsystems, Inc.PMA supplementDec 18, 2025FDA
Channel Medsystems, Inc.PMA supplementSep 15, 2026FDA
Channel Medsystems, Inc.PMA supplementNov 3, 2026FDA

Explore the linked device profile

Other records with product code MNB

Product / regulatory recordCompanyPathwayDecision dateSource
Axora Medical, Inc.PMA supplementNov 5, 2026FDA
MICROCUBE, LLCPMA supplementJul 13, 2026FDA
Axora Medical, Inc.PMA supplementFeb 12, 2026FDA
Hologic, Inc.PMA supplementDec 17, 2025FDA
Axora Medical, Inc.PMA approvalJul 27, 2015FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Channel Medsystems, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5858 Horton St., Suite 200, Emeryville, CA, 94608

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records